56 results about "Mouse tumor" patented technology

The invention belongs to the technical field of anti-tumor, and discloses application of HP and ICT combined anti-PD-1 inhibitor hydrogel in residual cancer recurrence after IRFA. The excellent drug delivery capacity of the hydrogel system is utilized, and the in-vivo local slow release effect of ICT and BMS202 can be remarkably amplified. Through synergistic treatment of the TAN and the MDSC, local and whole body adaptive immunoreactions can be efficiently activated, TAN is effectively reprogrammed to be in a tumor suppression type, infiltration of PMN-MDSC is reduced, and the conclusion is verified in a plurality of mouse tumor models in the chapter. Therefore, the HP (at) ICT / BMS provides a promising delivery strategy for improving the sensitivity of anti-PD-L1 treatment and efficiently preventing and treating latent residual cancer and metastasis after IRFA operation.

The present application relates to a kind of anaphalis contorta exosome extraction method and its application.The exosome is obtained by ultra-high speed centrifugation method from fresh anaphalis contorta, particle size is 160-200 nm, Zeta potential is-21.63±1.34 mV, with double membrane structure, mainly containing protein (such as resveratrol O-methyltransferase etc.) and phospholipid, polysaccharide content is only 12.5% of anaphalis contorta fresh medicine, and does not contain traditional active ingredient anaphalis contorta glycoside.Experiments show that anaphalis contorta exosome can be targeted to enrich in colorectal tissue, significantly improve AOM / DSS induced colorectal cancer model mouse tumor microenvironment, reduce tumor number, regulate T cell and macrophage ratio, and relieve pathological damage, better than anaphalis contorta fresh medicine.The mechanism is related to protein component, not polysaccharide or small molecule component.The anaphalis contorta exosome provided in the present application has simple preparation process, high safety, and has significant anti-colorectal cancer application potential.

Provided is use of a KIF18A inhibitor in preparing a medicament for treating ovarian cancer disease. Pharmacological studies have demonstrated that compounds 1-3 can inhibit the growth of ovarian cancer heterogeneous tumors, and a high dose of the compounds can cause tumor regression in mice. Compared with AMG650, a lower drug exposure of compounds 1-3 reduces the potential drug accumulation toxicity and possesses a significant therapeutic effect on ovarian cancer with good safety.

Provided are an anti-DLL3 antibody or an antigen-binding fragment thereof, a chimeric antigen receptor and a mutant thereof, and an enhanced chimeric antigen receptor comprising a PDL1 antagonist and an mIL7 element. Further provided are a nucleic acid encoding same, an expression cassette, vector and cell comprising the nucleic acid, a preparation method, and a use for preventing, treating, detecting, or diagnosing diseases related to DLL3. In the enhanced DLL3 chimeric antigen receptor, the PDL1 antagonist and the cell membrane IL7 cytokine element play a critical role in a long-term anti-tumor process. Animal efficacy experiments have shown complete tumor regression in all mice, indicating broad application prospects in the pharmaceutical field.

The invention relates to application of (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium in preparation of anti-cancer drugs, and belongs to the technical field of medical application, the structure of (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium is as shown in the following formula I, the (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium can inhibit the growth of gastric cancer cells, inhibit the proliferation, invasion and migration of the gastric cancer cells by promoting the autophagy and mitochondrial rupture of AGS and HGC-27 cells of the gastric cancer cells, and block the gastric cancer cells in the G1 stage. Furthermore, in-vivo experiments of mice prove that ZWK-3 can inhibit tumor growth of the mice, shows obvious dose dependence, and does not influence the body weight and visceral indexes of the mice at the same time. Formula I.

This invention belongs to the field of cancer drug preparation technology, specifically relating to the use of compounds or their salts in the preparation of cancer therapeutic drugs. The structure of the compound is shown in Formula I. The compound shown in Formula I can significantly inhibit tumor (e.g., breast cancer) growth. Compared with the blank control group, the tumors of mice treated with the compound shown in Formula I grow more slowly, are smaller and lighter, and have a significantly longer survival period. In addition, the compound shown in Formula I can be used in combination with Anti-PD1 to synergistically enhance the tumor inhibition effect.

The invention belongs to the technical field of tumor drugs, and provides application of timosaponin A1 in treatment of colorectal cancer, and the application is that timosaponin A1 is applied to preparation of drugs for treating colorectal cancer. The inhibition effect of timosaponin A1 on mitochondrial activity in colorectal cancer cells is evaluated through in-vitro cell experiments, two mouse tumor models, multi-omics analysis and other methods; results show that timosaponin A1 can stabilize a DHRS4-LONP2-TFAM compound in vivo and in vitro, so that TFAM degradation is promoted, mitochondrial biogenesis is inhibited, tumor cell growth is inhibited, and the aim of treating colorectal cancer is achieved.

The invention discloses application of an LPIN1 inhibitor in preparation of drugs for treating FLT3-ITD mutant acute myelogenous leukemia, reducing tumor load of a patient with the FLT3-ITD mutant acute myelogenous leukemia, improving the survival rate of the patient with the FLT3-ITD mutant acute myelogenous leukemia and / or reducing the proliferation activity of primary cells of the patient with the FLT3-ITD mutant acute myelogenous leukemia. The LPIN1 inhibitor for inhibiting lipid metabolism related enzyme LPIN1 can significantly induce apoptosis of FLT3-ITD mutant AML cells, has limited influence on non-mutant AML cells, and has mutation specificity. More importantly, the LPIN1 inhibitor (such as propranolol) and the FLT3 inhibitor (such as quinatinib) are combined for use, so that a synergistic anti-leukemia effect can be generated, and a remarkable anti-tumor effect is shown in vitro and in a mouse transplantation tumor model, so that the LPIN1 inhibitor and the FLT3 inhibitor have a good application prospect.

The preparation method of the fluorescent probe (S) comprises the following steps: adding absolute ethyl alcohol into p-phenylenediamine, refluxing and dissolving the solution (solution A) while heating at 80 DEG C, dissolving salicylaldehyde into a proper amount of absolute ethyl alcohol (solution B), dropwise adding the solution B into the solution A, and stirring to obtain a mixed solution; heating reflux is kept at 80 DEG C in the whole process, stirring is continuously carried out, and after reflux is carried out for 2 hours, filtering is carried out to obtain a faint yellow solid, namely the fluorescent probe (S). The fluorescent probe can specifically recognize hydrogen sulfide (H2S) under the interference of common ions, is strong in anti-interference capability and high in sensitivity, and can be used for real-time monitoring and fluorescence imaging of endogenous H2S of cells and mouse tumors.

The invention relates to the technical field of biological medicine, and discloses a lentiviral vector for specifically targeting a target cell and a construction method and application thereof, the lentiviral vector comprises: (1) an antigen targeting artificial protein receptor, the receptor comprising a target cell surface antigen binding domain and a transmembrane domain; (2) a mutated Moreton vesicular disease virus envelope protein; and (3) an expression cassette, wherein the expression cassette comprises a heterologous transgene. The novel lentiviral vector based on the mutated Moreton vesicular disease virus envelope, provided by the invention, can realize specific infection on target cells in vitro and in vivo, and compared with a vesicular stomatitis virus envelope VSV-G, the lentiviral vector constructed based on mutated Moreton vesicular disease virus envelope protein is better in stability in serum, and has a good application prospect. The efficiency of specifically infecting target cells is higher, and the drug effect in a mouse tumor model is more prominent.

The application belongs to the field of biological medicine, and relates to an anti-mouse integrin CD103 nanobody and application. The anti-mouse integrin CD103 nanobody comprises three complementarity determining regions CDR1, CDR2 and CDR3; wherein the amino acid sequence of CDR1 is a sequence or a high homology sequence shown in one of SEQ ID NO:1 to SEQ ID NO:4, the amino acid sequence of CDR2 is a sequence or a high homology sequence shown in one of SEQ ID NO:5 to SEQ ID NO:8, and the amino acid sequence of CDR3 is a sequence or a high homology sequence shown in one of SEQ ID NO:9 to SEQ ID NO:12. The application relates to the anti-mouse integrin CD103 nanobody and a preparation method thereof 18 The F-CYNB nanobody probe can realize targeted imaging of myocardial fibrosis, immune imaging of mouse tumors, and prediction of the effect of tumor immunotherapy.

The invention belongs to the technical field of medicines, and particularly relates to an experimental method for treating liver cancer by using oleanolic acid. Comprising an in-vitro experiment method and an in-vivo experiment method. The in-vitro experiment method comprises the following steps: S1, cell culture; s2, cell proliferation and migration; s3, detecting cell apoptosis and a cell cycle; s4, performing immunoblotting; s5, carrying out real-time quantitative PCR; the in-vivo experiment method comprises the following steps: step 1, performing chick embryo chorioallantoic model experiment; and 2, carrying out tumor-bearing experiment, treatment and tissue sampling on the mouse. The application of the oleanolic acid in liver cancer treatment is systematically researched for the first time, it is found that the oleanolic acid has the remarkable effects of inhibiting proliferation, inducing apoptosis, resisting angiogenesis and the like on liver tumors through the synergistic effect of multiple mechanisms, the remarkable curative effect on cancer mice is achieved, and a new medicine choice is provided for liver cancer treatment.

The application discloses a kind of mouse tumor cell culture devices, including device ontology, multiple placing racks are installed in device ontology, multiple placing racks top are all set with placing groove, the inside of multiple placing racks is all provided with access mechanism, access mechanism includes multiple placing plate, the inside of multiple placing plate is all separated into multiple placing chamber by multiple partition, the inside of multiple placing chamber is provided with correction mechanism, and drive mechanism is provided in device ontology.In the application, when multiple culture dishes need to be placed in the device ontology for cultivation, the access mechanism provided in the device ontology can be used to place the multiple culture dishes one by one, without manually placing and adjusting the spacing of the multiple culture dishes repeatedly, improving the efficiency of placing the multiple culture dishes in the device ontology, reducing the time of the culture dishes in the external environment, and improving the survival rate of mouse tumor cell cultivation.

The invention discloses a Kmt2c-knocked-out CD8 + T cell, a Kmt2c-knocked-out CAR-T cell, a construction method of the Kmt2c-knocked-out CD8 + T cell and a construction method of the Kmt2c-knocked-out CAR-T cell and application of the Kmt2c Experiments prove that the infiltration number of the CD8 + T cells in tumor tissues of mice adoptively knocked out of the CD8 + T cells of the Kmt2c is obviously increased, tumor growth can be inhibited, it is indicated that the CD8 + T cells knocked out of the Kmt2c can enhance the tumor killing capacity of the CD8 + T cells, and the CD8 + T cells have the potential of preparing drugs for enhancing anti-tumor immune response; mouse tumors of CAR-T cells adoptively reducing Kmt2c expression are remarkably reduced, and the infiltration quantity of the CAR-T cells in tumor tissues is remarkably increased, so that the Kmt2c deletion type CAR-T cells can effectively inhibit tumor growth. Besides, through combined use of the Kmt2c deletion type CAR-T cell and the PD-1 antibody, it is found that the inhibition of the dryness of the Kmt2c deletion type CAR-T cell can be better improved through PD-1 antibody treatment, and the anti-tumor capacity of the Kmt2c deletion type CAR-T cell is effectively improved.

The invention provides preparation and anti-tumor application of size-controllable porphyrin photosensitive nanoparticles, the porphyrin photosensitive nanoparticles are formed by assembling a porphyrin photosensitizer and aromatic drug molecules through an anti-solvent method, and the size range of the porphyrin photosensitive nanoparticles is 10-5000 nm. The photo-thermal performance of the porphyrin photosensitive nanoparticles is obviously improved. A mouse tumor model shows that the nano-particles coated with the cell membrane can be enriched at the tumor part, the in-vivo circulation time of the nano-particles is prolonged, and the phototherapy effect is remarkable when illumination is given. The nano-drug and the treatment mode thereof have good application prospects in the aspects of drug delivery and tumor treatment.

The invention relates to the technical field of supramolecular chemistry, in particular to a tetradentate pyridine ligand, a near-infrared two-region fluorescent metal cage as well as a preparation method and application of the tetradentate pyridine ligand and the near-infrared two-region fluorescent metal cage. The structural formula of the tetradentate pyridine ligand is shown in the specification, R is shown in the specification, and the element X is S or Se. The tetradentate pyridine ligand disclosed by the invention is a typical tetradentate pyridine ligand with a D-pi-A-pi-D structure and has strong near-infrared absorption capacity and efficient near-infrared two-region emission, and absorbed photon energy can be released in a fluorescent form; therefore, the metal cage prepared from the metal nano-material can be applied to in-vivo near-infrared two-region fluorescence imaging of mouse tumors. Due to the small ground state-excited state energy gap difference of the tetradentate pyridine ligand, photon energy absorbed by the metal cage prepared from the tetradentate pyridine ligand can also be released in the form of non-radiative transition, namely heat, so that the metal cage can be further applied to photo-thermal imaging and photo-thermal treatment and can play a complementary role with near-infrared two-region fluorescence imaging, and the in-vivo imaging quality is improved.

The invention relates to the technical field of biological medicine, and discloses a lentiviral vector and a construction method and application thereof, the lentiviral vector comprises: (1) an antigen-targeted artificial protein receptor, the receptor comprising a target cell surface antigen binding domain and a transmembrane domain; (2) a mutated Maraba virus envelope protein; and (3) an expression cassette, wherein the expression cassette comprises a heterologous transgene. The novel lentiviral vector based on the mutated Maraba virus envelope provided by the invention can realize specific infection on target cells in vitro and in vivo, and compared with a vesicular stomatitis virus envelope VSV-G, the lentiviral vector constructed on the basis of the mutated Maraba virus envelope protein has better stability in serum, and can be used for preparing a novel lentiviral vector of the mutated Maraba virus envelope. The efficiency of specifically infecting target cells is higher, and the drug effect in a mouse tumor model is more prominent.

This invention discloses a class of afterglow molecules, their preparation method, and applications, belonging to the field of biomedical optical imaging materials. By performing a Knoevenagel reaction between compound 2 (4-substituted-2,6-dicarboxyphenol) and N-substituted-2-methylbenzothiazolium bromide, inactive self-sustaining afterglow molecules QCAs are obtained. QCAs integrate reactive oxygen species generation, high-energy intermediate formation, and luminescence functions, possessing advantages such as simplified structure, low energy dissipation, and high reliability. Furthermore, an activatable self-sustaining afterglow molecule, P-QCA5, is also proposed. P-QCA5, modified with a phenylboronic acid group, can specifically respond to ONOO. ‑ It also activates the afterglow signal; leveraging its inherent low background and high signal-to-noise ratio, it successfully achieved precise imaging of mouse tumor models and Parkinson's disease (PD) models. Compared to traditional fluorescence imaging, which requires real-time excitation, afterglow imaging does not require real-time external light excitation, thus avoiding interference from tissue autofluorescence. It has a higher signal-to-noise ratio and deeper tissue detection depth, making it a promising bioimaging optical probe.

The invention discloses a fusion protein of neutrophil elastase as well as a preparation method and application of the fusion protein. The fusion protein comprises an optimized human neutrophil elastase (ELANE) fragment and an optimized human alpha2-macroglobulin (A2M) fragment; the amino acid sequence of the fusion protein is as shown in SEQ ID NO.8. The use of ELANE is limited due to intolerance to serine protease inhibitors (such as alpha-1-antitrypsin, A1AT). The optimized ELANE fragment and the optimized A2M fragment are connected to form the fusion protein, the fusion protein has high enzymatic activity, the tolerance to A1AT is greatly improved, and 83.3% of enzyme activity can still be maintained after the fusion protein acts for 2 hours through high-concentration A1AT (19200 nM). The fusion protein can efficiently eliminate mouse tumors and is safe to mice. The fusion protein is simple in preparation process and easy to industrially amplify, and a new strategy is provided for tumor treatment.

The application belongs to the field of organic molecule fluorescent probe, and a small molecule fluorescent probe HX is rationally designed, and the integration of diagnosis and treatment is realized by monitoring the related physical properties of tumor microenvironment and the photodynamic therapy of tumor. The tumor microenvironment of solid tumor usually has the characteristics of low pH, high viscosity, low oxygen and the like, and it is of great significance to carry out real-time monitoring and effective inhibition on tumor tissue based on the characteristic parameters of tumor site. Herein, a near-infrared fluorescent probe HX is designed, the probe does not respond to the change of surrounding viscosity in a high pH environment, however, in a low pH microenvironment of tumor, the "Donor-π-Acceptor (D-π-A)" structure thereof is opened, and sensitive viscosity response characteristics are exhibited, so that the dynamic monitoring of the tumor microenvironment is realized. In addition, through structure optimization, it is also confirmed that the probe can be used as a photosensitizer with type I reaction for photodynamic therapy of tumor tissue under hypoxic conditions. With the help of a mouse tumor model in vivo, it is confirmed that the probe HX not only has the ability to identify tumor tissue and normal tissue, but also has excellent tumor inhibition effect and good biocompatibility under hypoxic conditions, thereby providing a new technology for the diagnosis and treatment integration design of tumor diseases.

The present application relates to the field of radiopharmaceutical chemistry and clinical nuclear medicine technology, and particularly relates to a neurotensin receptor subtype 1 (NTSR1) antagonist derivative and application thereof. A radioactive preparation obtained by labeling the NTSR1 antagonist derivative with a radionuclide is simple to prepare, has high radiochemical purity, good stability, high uptake in the tumor site of a tumor-bearing mouse and a high target-to-non-target ratio, and has specific binding with NTSR1 in the tumor, and is a novel tumor radioactive drug with promotional application value.

The invention relates to the technical field of synthetic biology and immunotherapy, in particular to an immune gene combination fragment responding to a tumor microenvironment, a recombinant plasmid, probiotics and application of the immune gene combination fragment, the recombinant plasmid and the probiotics. The preparation method comprises the following steps: selecting phytobacterium plantarum, casei casei, casei paracasei, streptococcus thermophilus and lactococcus lactis as a probiotic chassis, further designing and assembling an immune gene combination fragment of immune checkpoint inhibitors (PD-L1 and CTLA-4), and uploading the immune gene combination fragment to the bacterial strain to construct customized probiotics, so as to prepare the immune checkpoint inhibitors (PD-L1 and CTLA-4). The in-vitro expression condition is researched; it is found that in a mouse tumor model, the customized probiotics can release PD-L1 and CTLA-4 nano antibodies at the tumor site, the tumor microenvironment is reversed, the immune system is mobilized, and the anti-tumor effect is enhanced. The research is expected to provide a safe and efficient anti-tumor strategy for tumor treatment, and new hope is brought to tumor patients.

The invention relates to the technical field of vaccine development, and particularly discloses a non-concentration dependent tumor vaccine and a preparation method and application thereof.The preparation method of the non-concentration dependent tumor vaccine comprises the steps that mouse tumor tissue is obtained and broken to obtain tumor cell lysis buffer, CpG freeze-dried powder and dopamine powder are added, and a water-phase solution is obtained; the preparation method comprises the following steps: dissolving IND and Los powder in medium-chain triglyceride, adding Tween 80 and PEG400 according to a ratio of the medium-chain triglyceride to Tween 80 to PEG400 of 30: 50: 20, and uniformly mixing to obtain an SNEDDS concentrated solution; and uniformly mixing the SNEDDS concentrated solution with the water phase solution to obtain a mixed system, and standing for 12-16 hours to obtain the personalized non-concentration dependent tumor vaccine. The personalized non-concentration dependent tumor vaccine prepared by the invention can greatly reduce the number of required tumor cells, and still can initiate potent anti-tumor immune response.

The present application relates to the field of pharmaceutical preparations, and particularly relates to application of NQO1 as a target point in preparation of a drug for head and neck squamous cell carcinoma. The present application finds that NQO1 is specifically highly expressed in HNSCC tumor cells, the expression level thereof is significantly negatively correlated with an adverse prognosis of a patient, and NQO1 not only promotes proliferation, migration and in-vivo tumorigenic ability of HNSCC cells, but also participates in regulation of a bithionol death process, which indicates that the NQO1 gene can be used as a key target point for enhancing immunotherapy of HNSCC tumors. In addition, compared with a single-drug treatment group, tumor growth of a mouse in a 'doubled coumarin + anti-PD-L1 antibody' combined treatment group is most effectively inhibited, and the tumor volume and weight are significantly reduced, which first proves that targeted inhibition of NQO1 can significantly sensitize PD-1 / PD-L1 immune checkpoint blocking therapy, and a significant immune synergistic effect is realized in head and neck squamous cell carcinoma. The finding provides an innovative combined treatment strategy and a precise intervention target point for overcoming current clinical problems such as a low response rate and easy drug resistance in immunotherapy of head and neck squamous cell carcinoma.

The invention belongs to the field of medicines, and discloses an antibody conjugate, the antibody conjugate is obtained by coupling a connecting structure, bortezomib and an antibody, the antibody conjugate has extremely strong drug sensitivity, and when the antibody conjugate is singly used or combined with cis-platinum, the antibody conjugate shows a remarkable inhibition effect on activity of proteasomes in MDA-MB-231 cells and mouse tumors. Meanwhile, the invention also discloses application and a medicine based on the antibody conjugate.

The invention discloses application of Elov16 as a target spot in preparation of a medicine for treating or preventing colorectal cancer, discovers that Elov16 inhibits colorectal cancer progress through a stearic acid-MFN1 axis, and belongs to the technical field of biology. Elov16 is low in expression in colorectal cancer tissue and predicts poor prognosis, and deletion of Elov16 causes reduction of stearic acid level, and induces enhancement of ubiquitination degradation of mitochondrial fusion protein MFN1 and fragmentation of mitochondria, so that tumor growth is promoted. The exogenous supplement of stearic acid can completely reverse the tumor promoting effect of Elov16 deletion in vivo and in vitro, so that the tumor volume of a mouse is reduced by more than 60%, and the effect has fatty acid specificity. The invention provides preparation application of a medicine taking an Elovl6-stearic acid-MFN1 axis as a target spot, a curative effect prediction kit and a genetic engineering mouse model, establishes an intervention strategy of an Elovl6-stearic acid-MFN1 regulation axis, provides a safe, effective and convenient nutrition intervention new way for precise treatment of colorectal cancer, and has great clinical transformation value.

A method for inducing and activating a conventional dendritic cell subset, the method comprising the following steps: A. seeding human peripheral blood stem cells or umbilical cord blood stem cells in a plate, and performing expansion culture using a basal medium supplemented with cytokine 1; B. performing in vitro induced differentiation culture on the cells after the expansion culture using a basal medium supplemented with cytokine 2; C. sorting the differentiated cells to obtain pure cDC1 cells; and D. performing activation culture on the pure cDC1 cells using a basal medium supplemented with a stimulator to obtain activated cDC1 cells. A large number of human primary cDC1 are obtained by means of induction from umbilical cord blood stem cells, and the anti-tumor ability of cDC1 is then activated by means of a combination of stimulators. Moreover, the feasibility and efficacy of cDC1 for tumor therapy are verified for the first time by means of a humanized mouse tumor model.

The invention belongs to the field of medicine preparation, and particularly relates to a nano delivery carrier of IL-22BPmRNA (Interleukin-22BPmRNA). The invention aims to overcome the defect of less types of ionizable phospholipids for preparing LNP delivery mRNA. The technical scheme for solving the technical problem is to provide a nano delivery carrier of IL-22BPmRNA, which is prepared on the basis of a novel ionizable phospholipid molecule capable of being used for preparing a nucleic acid delivery carrier. The nano delivery carrier of the IL-22BPmRNA, disclosed by the invention, is good in stability. Experiments show that therapeutic RNA can be efficiently delivered to various human and mouse tumor cells, high-level protein expression is realized, and the polypeptide has unique advantages and good application prospects in the field.

The invention belongs to the technical field of biomedicine, and particularly relates to application of SDAD1 as a target spot to preparation of a medicine for treating diffuse large B-cell lymphoma. The invention provides a biomarker SDAD1 gene or SDAD1 protein for auxiliary diagnosis of diffuse large B-cell lymphoma for the first time. The invention discovers that the progression-free lifetime and the total lifetime of patients with high SDAD1 expression are obviously shortened compared with those of patients with low expression for the first time, which prompts that the high expression of SDAD1 is related to poor prognosis of DLBCL patients. The LC1-DNAzyme drug capable of efficiently inhibiting SDAD1 gene expression is prepared, the effects of specifically recognizing DLBCL cells, inhibiting tumor cell proliferation and promoting tumor cell apoptosis can be achieved, and it is verified through a mouse tumor-bearing model that the drug can effectively treat lymphoma and is good in safety.

The present application relates to the technical field of biological materials, and particularly relates to in-situ programmed synthesis of quantum dots of cells and a preparation method and application thereof. The core innovation of the present application is that a multi-level nano-synthesizer with responsiveness is designed, and a bottleneck that functional nano-materials cannot be in-situ synthesized at the level of living bodies and cells is broken. The present application promotes the development of biological synthesis of nano-materials, especially in-situ programmed synthesis of quantum dots. After the unique nano-synthesizer of the present application is internalized by cells, a diselenide bond is cleaved by glutathione to generate active selenium species, then the silicon shell skeleton collapses, silver precursors are released, and quantum dots are generated by reaction with selenium precursors. The quantum dots provided by the present application can be in-situ synthesized at tumor sites, induce oxidative stress, combine with the photothermal effect of near-infrared quantum dots, and finally lead to tumor cell apoptosis or necrosis, effectively delaying the development of tumors in tumor-bearing mice and prolonging the survival period of the mice.